US 12,404,276 B2
Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases
Feng Ren, Shanghai (CN); Xianlian Wang, Shanghai (CN); Yongmei Xu, Shanghai (CN); Chunlin Chen, Shanghai (CN); and Jinna Cai, Shanghai (CN)
Assigned to SHANGHAI MEDICILON INC., Shanghai (CN); and MEDICILON PRECLINICAL RESEARCH (SHANGHAI) LLC., Shanghai (CN)
Appl. No. 17/630,122
Filed by SHANGHAI MEDICILON INC., Shanghai (CN); and MEDICILON PRECLINICAL RESEARCH (SHANGHAI) LLC., Shanghai (CN)
PCT Filed Aug. 26, 2019, PCT No. PCT/CN2019/102522
§ 371(c)(1), (2) Date Jan. 25, 2022,
PCT Pub. No. WO2021/017065, PCT Pub. Date Feb. 4, 2021.
Claims priority of application No. 201910679800.3 (CN), filed on Jul. 26, 2019.
Prior Publication US 2022/0259214 A1, Aug. 18, 2022
Int. Cl. A61K 31/4162 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 4 Claims
 
1. A compound represented by formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,
wherein:
X is CH or N;
R1 is halogen;
R2 is H, halogen, or OH;
R3 is H or C1-3 alkyl;
Y is —CH2—, —NH—, or —O—; and
Z is —CH2—, —NH—, or —O—;
with the proviso that Y and Z are not both —CH2—.
 
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and the compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.